Status and phase
Conditions
Treatments
About
The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease and Alcoholic Hepatitis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
•Patients over 18, under 70 years of age
The chronic alcohol intake patients
Over 1.5 ratio of AST to ALT
Patients who have chronoc alcohol disease
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
90 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal